secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2024-05-23T23:59:59+00:00
Accession:  0000950170-24-063707
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics stockholders approve 2024 equity plans and re-elect directors at annual meeting
--------------------------------------------------------------------------------

- Stockholders re-elected Brian Lian (50.5M for, 17.4M withheld) and Lawson Macartney (22.3M for, 45.7M withheld) as Class III directors.
- 2024 Equity Incentive Plan approved (48.5M for, 19.3M against).
- 2024 Employee Stock Purchase Plan approved (67.1M for, 0.7M against).
- Advisory say-on-pay approved (63.2M for, 4.5M against).
- Ratification of Marcum LLP as auditor for FY2024 approved (87.4M for, 0.7M against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024063707/0000950170-24-063707-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024063707/vktx-20240521.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-063707

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer